Dall, Genevieve
Vandenberg, Cassandra J. http://orcid.org/0000-0002-8891-8873
Nesic, Ksenija
Ratnayake, Gayanie
Zhu, Wenying
Vissers, Joseph H. A.
Bedő, Justin
Penington, Jocelyn
Wakefield, Matthew J.
Kee, Damien
Carmagnac, Amandine
Lim, Ratana
Shield-Artin, Kristy
Milesi, Briony
Lobley, Amanda
Kyran, Elizabeth L.
O’Grady, Emily
Tram, Joshua
Zhou, Warren
Nugawela, Devindee
Stewart, Kym Pham
Caldwell, Reece
Papadopoulos, Lia
Ng, Ashley P.
Dobrovic, Alexander
Fox, Stephen B.
McNally, Orla
Power, Jeremy D.
Meniawy, Tarek
Tan, Teng Han
Collins, Ian M.
Klein, Oliver
Barnett, Stephen
Olesen, Inger
Hamilton, Anne
Hofmann, Oliver
Grimmond, Sean
Papenfuss, Anthony T.
Scott, Clare L.
Barker, Holly E.
Funding for this research was provided by:
Australian and New Zealand Gynaecological Oncology Group (ACF-07544)
National Health and Medical Research Council (1062702)
Stafford Fox Medical Research Foundation
Cancer Council Victoria (1186314)
Victorian Cancer Agency (CRF10-20, CRF16014)
Article History
Received: 14 February 2023
Accepted: 25 April 2023
First Online: 4 May 2023
Declarations
:
: Informed consent was obtained from all subjects involved in the study. This study was conducted in accordance with the Australian National Statement of Ethical Conduct in Human Research (2007) approved by Melbourne Health Human Research Ethics Committee (2015.300). Additional approval was obtained from the Human Research Ethics Committee at the Peter MacCallum Cancer Centre. All animal experiments were conducted according to the National Health and Medical Research Council Australian Code for the Care and Use of Animals for Scientific Purposes 8th Edition, 2013 (updated 2021), and under the approval of the WEHI Animal Ethics Committee (2019.024).
: Consent for publication was obtained from patients with uLMS who were studied in detail in this manuscript.
: CLS declares Advisory Boards for AstraZeneca, Clovis Oncology, Roche, Eisai Inc, Sierra Oncology, Takeda, MSD and Grant/Research support from AstraZeneca, Clovis Oncology, Eisai Inc, Sierra Oncology, Boehringer Ingelheim, Roche and Beigene. Other authors declare no conflicts of interest.